Aurobindo Pharma Q1 Results FY27: Date, Revenue Estimates and What to Expect

Aurobindo Pharma Q1 Results FY27 expected July-August 2026. CMP Rs.1555.0 on NSE. Revenue estimate Rs.8,611-9,698 Cr. Analyst target Rs.1,396-1,638.

Get Free Investment Predictions and Aurobindo Pharma Research at Univest

Aurobindo Pharma is expected to announce its Q1 FY27 (April to June 2026) financial results in July or August 2026. As of July 2026, the stock trades around Rs.1555.0 on NSE. This Aurobindo Pharma Q1 Results FY27 preview covers revenue prediction, Q1 expectations, key catalysts and risks, technical levels and the 12-month analyst price target.

India’s pharmaceutical and healthcare sector is navigating growth opportunities heading into Q1 Results FY27. The Aurobindo Pharma Q1 Results FY27 Q1 prediction and Q1 expectations will reflect these sector dynamics.

This Aurobindo Pharma Q1 Results FY27 Q1 result preview covers Q1 FY27 estimates, Q1 FY26 actual performance for context, key catalysts and risks, and the 12-month analyst price target.

About Aurobindo Pharma

Aurobindo Pharma Q1 Results FY27 will be a critical Q1 result preview for investors. Aurobindo Pharma is a pharmaceutical and healthcare company listed on the National Stock Exchange and Bombay Stock Exchange. Q1 FY27 (April to June 2026) results will be a key data point for assessing the full-year FY27 earnings trajectory. Any material beat or miss in the Aurobindo Pharma Q1 Results FY27 Q1 result preview will likely drive meaningful stock price movement.

Aurobindo Pharma reported Revenue of Rs.7,868 Cr in Q1 FY26, forming the year-on-year comparison base for the Aurobindo Pharma Q1 Results FY27 estimate. The Aurobindo Pharma Q1 Results FY27 Q1 expectations point to revenue of Rs.8,611-9,698 Cr.

Aurobindo Pharma Q1 FY27 Estimates: What to Expect

Aurobindo Pharma Q1 Results FY27 revenue prediction, PAT estimate, results date and 12-month analyst target.

Source: Q1 FY26 actuals from company filings. Aurobindo Pharma Q1 Results FY27 estimates (Q1 prediction) are Uniresearch trailing-growth projections. July 2026. Subject to change.

Key Catalysts to Watch in Aurobindo Pharma Q1 Results FY27

1. Domestic Formulation Volume Growth

India’s domestic pharma market is growing at 8-10% annually led by chronic therapies and expanding healthcare access. Analysts will scrutinise management commentary on this point closely during the Aurobindo Pharma Q1 Results FY27 earnings call. This is a core Q1 prediction metric watched by investors.

2. Management Guidance for FY27

Full-year FY27 revenue and EBITDA margin guidance from the Aurobindo Pharma management team will be a key determinant of the stock’s reaction to Q1 Results FY27. Q1 expectations on guidance typically drive 60-70% of post-result price movement for pharmaceutical and healthcare companies.

3. Sector Macro Commentary

Management commentary on sector-specific dynamics including demand trends, input cost pressures, and competitive landscape will provide forward guidance visibility. This is one of the key Aurobindo Pharma Q1 Results FY27 Q1 expectations investors will monitor for sector direction.

Key Risks for Aurobindo Pharma Q1 Results FY27

• USFDA regulatory warnings or Form 483 observations can disrupt US generic export revenues.
• Currency volatility and global macro uncertainty can impact revenue from export-facing business segments.
• Regulatory changes and compliance requirements can increase operating costs.

Track Aurobindo Pharma Q1 Results FY27 Fundamentals on Univest

Aurobindo Pharma Q1 FY26 Performance: Setting the Context

To understand Aurobindo Pharma Q1 Results FY27 Q1 expectations, it is important to contextualise Q1 FY26 (April to June 2025) performance. Aurobindo Pharma reported Q1 FY26 Revenue of Rs.7,868 Cr and PAT of Rs.824 Cr. This provides the year-on-year comparison base against which Aurobindo Pharma Q1 Results FY27 Q1 expectations will be assessed. Any material beat or miss in the Aurobindo Pharma Q1 Results FY27 Q1 result preview will likely drive meaningful stock price movement on results day.

Technical Analysis: Aurobindo Pharma Share Price Levels

• Current Market Price: Rs.1555.0 on NSE (July 1, 2026), tracking Aurobindo Pharma Q1 Results FY27
• For the latest 52-week high/low levels, track Aurobindo Pharma live on the NSE portal or Univest Screener
• Aurobindo Pharma Q1 Results FY27 Q1 expectations: Revenue in the Rs.8,611-9,698 Cr range
• The stock’s FY27 trajectory will be shaped by Aurobindo Pharma Q1 Results FY27 outcome and management guidance

Download the Univest iOS App or Univest Android App to track Aurobindo Pharma’s live price, charts and receive SEBI-backed research alerts.

Aurobindo Pharma Share Price Target: Analyst Estimates

Short-Term Target (3 to 6 Months)

In the near term, Aurobindo Pharma’s share price will be primarily driven by the Aurobindo Pharma Q1 Results FY27 outcome relative to estimates. A beat on Revenue or PAT, combined with positive management guidance for FY27, could drive the stock toward the higher end of analyst expectations. Analyst Q1 prediction: a beat on Aurobindo Pharma Q1 Results FY27 Revenue or PAT could drive the stock higher. Short-term target: Rs.1,312-1,540.

12-Month Target (Uniresearch Estimate)

The Aurobindo Pharma Q1 Results FY27 12-month price target is estimated at Rs.1,396-1,638, based on Uniresearch trailing-growth estimates. This is contingent on Aurobindo Pharma Q1 Results FY27 meeting Q1 expectations and FY27 guidance being constructive.

Long-Term View (FY27 to FY28)

Longer-term, the Aurobindo Pharma Q1 Results FY27 Q1 result preview will anchor the FY27-FY28 outlook. Longer-term, Aurobindo Pharma’s share price trajectory will depend on sector growth trends, market share dynamics, management execution quality, and India’s overall macroeconomic environment.

What to Watch on Aurobindo Pharma Q1 Results FY27 Day

• Aurobindo Pharma Q1 Results FY27 Revenue and PAT numbers relative to Q1 Results FY27 estimates of Rs.8,611-9,698 Cr Revenue
• Aurobindo Pharma Q1 Results FY27 management guidance: full-year FY27 Revenue and EBITDA margin direction
• Aurobindo Pharma Q1 Results FY27 sector-specific operating metrics: domestic formulation volume growth and management guidance
• Any dividend announcement or capital allocation guidance
• Management commentary on macro headwinds including USFDA regulatory warnings or Form 483 observations can disrupt US generic export

Conclusion

Aurobindo Pharma Q1 Results FY27 is one of the key Q1 result preview events for India’s pharmaceutical and healthcare sector in the July-August 2026 results season. This Aurobindo Pharma Q1 Results FY27 Q1 result preview is anchored on Q1 expectations of Rs.8,611-9,698 Cr Revenue. Monitor the Univest research platform for Aurobindo Pharma Q1 Results FY27 real-time commentary, Q1 predictions and Q1 expectations post the Q1 result preview declaration.

Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice or a stock recommendation. All estimates, analyst targets, and financial projections are based on Uniresearch trailing-growth analysis and are subject to change. Investing in stocks involves market risk. Please consult a SEBI-registered financial advisor before making any investment decision. SEBI RA INH000013776.

Frequently Asked Questions on Aurobindo Pharma Q1 Results FY27

When is Aurobindo Pharma Q1 FY27 results date?

Ans. The Aurobindo Pharma Q1 FY27 results date has not been officially announced yet. Q1 FY27 (April to June 2026) results are typically declared in July or August 2026. Check the NSE or BSE filing portal for the exact Aurobindo Pharma Q1 Results FY27 results date.

What is the Aurobindo Pharma Q1 FY27 revenue estimate?

Ans. The Aurobindo Pharma Q1 Results FY27 revenue prediction (Q1 FY27 estimate) based on Uniresearch trailing-growth analysis is Rs.8,611 to Rs.9,698 Cr. Actual Q1 Results FY27 revenue may differ from this Q1 prediction.

What is the Aurobindo Pharma share price target?

Ans. The Aurobindo Pharma Q1 Results FY27 12-month price target is estimated at Rs.1,396-1,638 based on Uniresearch trailing-growth estimates. This is contingent on Q1 Results FY27 meeting Q1 expectations and FY27 guidance being constructive.

Is Aurobindo Pharma a good buy before Q1 FY27 results?

Ans. Investing ahead of Aurobindo Pharma Q1 Results FY27 carries earnings risk. Q1 expectations and Q1 predictions vary, and quarterly results can cause sharp price moves. Assess whether Aurobindo Pharma offers a good risk-reward at current levels relative to Q1 result preview scenarios. Consult a SEBI-registered financial advisor before any investment decision.

What should I watch for in Aurobindo Pharma Q1 FY27 results?

Ans. Key metrics to monitor for Aurobindo Pharma Q1 Results FY27 results: Revenue performance versus the Q1 prediction of Rs.8,611-9,698 Cr; PAT versus estimate; management guidance for FY27; domestic formulation volume growth progress; and management commentary on macro headwinds including USFDA regulatory warnings or Form 483 observations can disrupt US generic export.

Where can I find Aurobindo Pharma Q1 FY27 results?

Ans. Aurobindo Pharma Q1 Results FY27 will be available on the BSE (bseindia.com) and NSE (nseindia.com) filing portals immediately after the board meeting. For real-time analysis, expert commentary, and updated Aurobindo Pharma Q1 Results FY27 Q1 prediction and Q1 expectations analysis after results are declared, download the Univest app.